Karo Pharma acquires product portfolio from LEO Pharma
Karo Pharma acquires a focused intimate care and dermatology product portfolio from the Danish pharmaceutical company LEO Pharma for 90 MEUR. The turnover of the acquired portfolio is estimated to 35 MEUR for the full year of 2019. Approximately 2/3 of the turnover comes from European markets. The portfolio consists of four anti-haemorrhoid products (Sheriproct[®], Doloproct[®], Neriproct[®] and Ultraproct[®]) and six dermatology products (Ultrabas[®], Ultralip[®], Ultraphil[®], Ultrasicc[®], Neribas[®] and Ultralan[®]). The anti-haemorrhoid product group constitutes the largest part